NCT05690945View on ClinicalTrials.gov

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

608

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

June 30, 2029

Study Completion Date

December 31, 2029

Conditions
Lung Cancer
Interventions
DRUG

QL1706

QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.

DRUG

Tilesizumab

Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY